EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Ingo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, Mehdi Touat, Katherine B Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust-Katz, Liam Welsh, Warren P Mason, François Ducray, Yoshie Umemura und 19 weitere

New England Journal of Medicine · 17.08.2023 · 389 (7) · 589-601

DOI: 10.1056/nejmoa2304194 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 17.08.2023. Verfasst von Ingo K Mellinghoff und 30 weiteren Autor:innen. Beteiligte Einrichtung: From Memorial Sloan Kettering Cancer Center, New York (I.K.M.); the Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.…. Hauptthemen laut MEDLINE: Glioma, Neoplasm Recurrence, Local, Antineoplastic Agents. Die Arbeit wurde bisher 845-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaNeoplasm Recurrence, LocalAntineoplastic AgentsHumansAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionDouble-Blind MethodIsocitrate DehydrogenasePyridinesEnzyme InhibitorsDiamines

Substanzen

Isocitrate DehydrogenasePyridinesAntineoplastic AgentsEnzyme InhibitorsIDH1 protein, humanvorasidenibDiaminesIDH2 protein, human

Autor:innen und Institutionen

  • From Memorial Sloan Kettering Cancer Center, New York (I.K.M.); the Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.B.); Tel Aviv Medical Center, Tel Aviv University, Tel Aviv (D.T.B., S…

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., …, & INDIGO Trial Investigators (2023). Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. New England Journal of Medicine, 389(7), 589-601. https://doi.org/10.1056/nejmoa2304194

Vancouver

Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. New England Journal of Medicine. 2023;389(7):589-601. doi:10.1056/nejmoa2304194

BibTeX
@article{Mellinghoff2023,
  author = {Mellinghoff, Ingo K and van den Bent, Martin J and Blumenthal, Deborah T and Touat, Mehdi and Peters, Katherine B and Clarke, Jennifer and Mendez, Joe and Yust-Katz, Shlomit and Welsh, Liam and Mason, Warren P and Ducray, François and Umemura, Yoshie and Nabors, Burt and Holdhoff, Matthias and Hottinger, Andreas F and Arakawa, Yoshiki and Sepulveda, Juan M and Wick, Wolfgang and Soffietti, Riccardo and Perry, James R and Giglio, Pierre and de la Fuente, Macarena and Maher, Elizabeth A and Schoenfeld, Steven and Zhao, Dan and Pandya, Shuchi S and Steelman, Lori and Hassan, Islam and Wen, Patrick Y and Cloughesy, Timothy F and INDIGO Trial Investigators, INDIGO Trial Investigators},
  title = {Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {7},
  pages = {589--601},
  doi = {10.1056/nejmoa2304194}
}
Kostenlos starten →